LIXTE BIOTECHNOLOGY HOLDINGS
Lixte Biotechnology Holdings, Inc. is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.
LIXTE BIOTECHNOLOGY HOLDINGS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2004-01-01
Address:
East Setauket, New York, United States
Country:
United States
Website Url:
http://www.lixte.com
Total Employee:
1+
Status:
Active
Contact:
(631) 830-7092
Total Funding:
10.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Apache
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
James Miser Chief Medical Officer @ Lixte Biotechnology Holdings
Chief Medical Officer
Gil Schwartzberg Consultant @ Lixte Biotechnology Holdings
Consultant
John S. Kovach Founder & CEO @ Lixte Biotechnology Holdings
Founder & CEO
2006-01-01
Founder
Stock Details
Official Site Inspections
http://www.lixte.com Semrush global rank: 1.24 M Semrush visits lastest month: 24.48 K
- Host name: 74-208-236-39.elastic-ssl.ui-r.com
- IP address: 74.208.236.39
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lixte Biotechnology Holdings"
LIXTE Biotechnology Holdings, Inc. (LIXT)
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances the efficacy of both chemotherapy and …See details»
Lixte Biotechnology Holdings, Inc. | LinkedIn
Lixte Board Member Prof. René Bernards is a member of the organization’s scientific committee, helping to identify and prioritize these challenges. Learn more by clicking the link below. # ...See details»
Lixte Biotechnology - Crunchbase Company Profile
Lixte Biotechnology is a clinical-stage public pharmaceutical company that focuses on discovering drugs for more effective treatments for cancer. Lixte …See details»
TEAM: Collective expertise in pioneering effective cancer therapies …
LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180 Pasadena, CA 91101. General Phone: (631) 830-7092 Investor Phone: (888) 289-5533 Fax: (631) 982-5050See details»
Lixte Biotechnology Holdings, Inc. (LIXT) - Yahoo Finance
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Corporate Governance Lixte Biotechnology Holdings, Inc.’s ISS Governance QualityScore as …See details»
LIXT - Lixte Biotechnology Holdings, Inc. - OTC Markets
Feb 25, 2025 Lixte Biotechnology Holdings, Inc. is a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has …See details»
Lixte Biotechnology Holdings (LIXT) Company Profile & Description
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer …See details»
Lixte Biotechnology - Funding, Financials, Valuation & Investors
Lixte Biotechnology is a clinical-stage pharmaceutical company that focuses on discovering drugs for effective cancer treatments. New. Resources. ... How much funding has this organization …See details»
LIXTE Biotechnology Provides Update On Progress with Proprietary ...
2 days ago Further bolstering of LIXTE’s intellectual property portfolio, with receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent …See details»
LIXTE Biotechnology Provides Update On Progress with …
2 days ago LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180 Pasadena, CA 91101 General Phone: (631) 830-7092 Investor Phone: (888) 289-5533 Fax: (631) 982-5050 Email: info@lixte.com LIXTE Biotechnology …See details»
Company Information :: LIXTE Biotechnology Holdings, Inc. (LIXT)
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances …See details»
LIXTE Biotechnology Holdings - Overview, News & Similar
May 20, 2024 LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments-- Three Clinical Trials Currently …See details»
Lixte Biotechnology Holdings, Inc. - Drug pipelines, Patents
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. …See details»
Lixte Biotechnology Holdings, Inc. (LIXT) - Yahoo Finance Canada
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer …See details»
Financial Information :: LIXTE Biotechnology Holdings, Inc. (LIXT)
LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180 Pasadena, CA 91101 General Phone: (631) 830-7092 Investor Phone: (888) 289-5533 Fax: (631) 982-5050 Email: …See details»
Lixte Biotechnology Holdings, Inc. Information - RocketReach
Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified …See details»
LIXTE Biotechnology Provides Update On Recent Activities and ...
Aug 19, 2024 -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the …See details»
LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And …
1 day ago (RTTNews) - LIXTE Biotechnology Holdings, Inc. (LIXT), on Thursday, announced the latest progress with its proprietary compound, LB-100, for the treatment of ovarian and …See details»
LIXTE Biotechnology Enters into Exclusive Immune Oncology …
Feb 26, 2024 LIXTE recently announced the entry of the first patient into a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1) …See details»
News & Events :: LIXTE Biotechnology Holdings, Inc. (LIXT)
Feb 25, 2025 LIXTE Biotechnology Holdings, Inc. 680 E Colorado Blvd., Suite 180 Pasadena, CA 91101 General Phone: (631) 830-7092 Investor Phone: (888) 289-5533 Fax: (631) 982 …See details»